STOCK TITAN

Caribou Biosciences, Inc. - CRBU STOCK NEWS

Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.

Caribou Biosciences, Inc. (CRBU) is a clinical-stage biotechnology company pioneering advancements in genome engineering. Leveraging revolutionary CRISPR-Cas9 technology, Caribou specializes in developing innovative cellular engineering solutions. Their technology, which pairs Cas9 with guide RNA to facilitate precise DNA modifications, is being harnessed for sophisticated gene knock-outs and knock-ins. Caribou's tools provide transformative capabilities across various sectors, including biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.

At the forefront of biopharmaceutical innovation, Caribou is dedicated to applying its proprietary CRISPR hybrid RNA-DNA (chRDNA) platform to create next-generation genome-edited cell therapies. Their pipeline includes allogeneic CAR-T and CAR-NK cell therapies, aimed at treating patients with hematologic malignancies and solid tumors.

Recent milestones include the FDA's feedback on a Phase 3 trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy targeting large B cell lymphoma (LBCL). The ongoing ANTLER Phase 1 trial has shown promising results, with CB-010 receiving Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations. Caribou is also expanding CB-010's potential application to lupus nephritis and extrarenal lupus, with a GALLOP Phase 1 trial planned for late 2024.

Financially, Caribou reported a net loss of $41.2 million for Q1 2024, with $345.9 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q1 2026. Their strategic partnerships, including a collaboration with Pfizer, have bolstered their financial standing.

Caribou continues to push the boundaries of genome editing with its chRDNA technology, significantly improving the precision of genome edits. Their commitment to transforming patient lives through cutting-edge science positions them as a leader in the biotech landscape.

Rhea-AI Summary

Caribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, announced its participation in several upcoming investor conferences. Significant events include:

  • Citi 17th Annual BioPharma Conference on September 8, 2022, at 11:20 am ET
  • H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 10:00 am ET
  • Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:40 pm ET
  • Jefferies Cell and Genetic Medicines Summit on September 29-30, 2022

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
conferences
-
Rhea-AI Summary

Caribou Biosciences (CRBU) reported significant progress in its clinical pipeline and a strong financial position with $366.1 million in cash as of June 30, 2022. The company achieved a 100% complete response rate in its CB-010 ANTLER Phase 1 trial for relapsed or refractory B cell non-Hodgkin lymphoma. Plans include enrolling more patients and submitting IND applications for CB-011 and CB-012 in late 2022 and 2023, respectively. Revenue from licensing and collaborations increased significantly, but R&D and G&A expenses also rose, leading to a net loss of $26.7 million for Q2 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.25%
Tags
-
Rhea-AI Summary

Caribou Biosciences (CRBU) reported promising results from its ANTLER Phase 1 trial for CB-010, an allogeneic CAR-T cell therapy. A 100% complete response (CR) rate was observed in six patients following a single dose, with 40% maintaining CR at six months. The first patient treated remained in CR for 12 months. The trial is now enrolling at a higher dosage, reflecting an initial positive safety profile and clinical activity. Additional data is expected by year-end 2022, suggesting potential advancements in CRISPR-edited therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.41%
Tags
Rhea-AI Summary

Caribou Biosciences, Inc. (Nasdaq: CRBU) will present additional clinical data from its ANTLER Phase 1 trial of CB-010, a CRISPR-edited CAR-T cell therapy for relapsed/refractory B cell non-Hodgkin lymphoma, during a webcast on June 10, 2022. The presentation will feature longer duration data from six patients treated at dose level 1. The live webcast begins at 8:00 am ET, and the poster will be showcased at the European Hematology Association 2022 Congress in Vienna. CB-010 represents a novel approach with a PD-1 knockout design aimed at enhancing antitumor activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
-
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) presented studies at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) on May 16, 2022, showcasing the enhanced specificity of its CRISPR hybrid RNA-DNA (chRDNA) guides for genome editing. Dr. Steve Kanner highlighted that these guides improve the efficacy and persistence of allogeneic cell therapies by minimizing off-target activities. The optimized chRDNA guides demonstrate superior precision in editing primary human T cells, reinforcing their potential in therapeutic applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
-
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) reported significant initial results from its ANTLER Phase 1 trial for CB-010, showing a 100% overall response rate (ORR) and 80% complete response rate (CR) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial treated 5 evaluable patients, all responding positively. CB-010 is notable as the first allogeneic CAR-T cell therapy with a PD-1 knockout, enhancing potential treatment efficacy. Data will be shared at the upcoming European Hematology Association Congress, with ongoing enrollment at a higher dose level planned.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.17%
Tags
none
Rhea-AI Summary

Caribou Biosciences has appointed David L. Johnson to its board of directors, enhancing its leadership as its pipeline of genome-edited cell therapies advances. With 30 years of experience, Johnson previously led global commercial efforts at Global Blood Therapeutics and held significant roles at Gilead Sciences. His expertise in building commercial infrastructure is expected to aid Caribou's progress, particularly in allogeneic cell therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.17%
Tags
management
-
Rhea-AI Summary

Caribou Biosciences (CRBU) reported financial results for Q1 2022, highlighting a cash position of $390.8 million. The company continues to advance its clinical pipeline with initial data from the ANTLER Phase 1 trial of CB-010 expected at the EHA 2022 Hybrid Congress. Plans include submitting an IND application for CB-011 in H2 2022 and ongoing research in allogeneic CAR-T and CAR-NK cell therapies. Revenues increased to $2.7 million, while R&D and G&A expenses rose significantly, contributing to a net loss of $19.1 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
-
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) has announced that CEO Rachel Haurwitz will participate in the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, at 8:00 am PT. The event will feature a fireside chat and will be available for live streaming on Caribou's website, with an archived version accessible for 30 days post-event. Caribou is focused on developing advanced CRISPR-based therapies for severe diseases, utilizing its proprietary Cas12a chRDNA technology for precise genome editing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
conferences
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) will present groundbreaking studies at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) from May 16-19, 2022. The studies demonstrate the superior specificity of Caribou’s chRDNA genome-editing technology in primary human T cells. The presentation, titled 'Conformational control of Cas endonucleases by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells', is scheduled for May 16 at 5:30 PM EDT. This innovative technology aims to enhance precision in genome editing, addressing potential off-target effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none

FAQ

What is the current stock price of Caribou Biosciences (CRBU)?

The current stock price of Caribou Biosciences (CRBU) is $2.34 as of November 4, 2024.

What is the market cap of Caribou Biosciences (CRBU)?

The market cap of Caribou Biosciences (CRBU) is approximately 212.8M.

What does Caribou Biosciences specialize in?

Caribou Biosciences specializes in genome engineering using CRISPR-Cas9 technology to develop innovative cellular engineering solutions.

What is CB-010?

CB-010 is Caribou's lead allogeneic anti-CD19 CAR-T cell therapy, currently in clinical trials for large B cell lymphoma and lupus.

What recent FDA feedback did Caribou receive?

The FDA provided feedback on a Phase 3 trial for CB-010, stating that the proposed comparator arm is acceptable.

How is Caribou's financial health?

Caribou reported a net loss of $41.2 million for Q1 2024, with $345.9 million in cash and equivalents, sufficient to fund operations into Q1 2026.

What is chRDNA technology?

chRDNA (CRISPR hybrid RNA-DNA) technology is Caribou's proprietary platform that allows for more precise genome editing compared to traditional methods.

What are the applications of Caribou's technology?

Applications include basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.

What designations has CB-010 received from the FDA?

CB-010 has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations.

What is the ANTLER trial?

The ANTLER trial is a Phase 1 clinical trial evaluating CB-010 in patients with large B cell lymphoma.

What is Caribou's collaboration with Pfizer?

Caribou's collaboration with Pfizer includes a $25 million equity investment, supporting their financial and developmental goals.

What upcoming trials are planned for CB-010?

Caribou plans to initiate the GALLOP Phase 1 trial for CB-010 in lupus nephritis and extrarenal lupus by the end of 2024.

Caribou Biosciences, Inc.

Nasdaq:CRBU

CRBU Rankings

CRBU Stock Data

212.80M
90.36M
10.03%
63.1%
12.74%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
BERKELEY